Safety Considerations and Provider Oversight Requirements GHK-Cu administration requires qualified provider oversight to ensure injection technique safety, sterility protocols, and appropriate dose selection
Unlike pharmaceutical sleep aids that cause next-day drowsiness, cognitive impairment, tolerance, and dependency, DSIP enhances sleep quality without sedative side effects, maintains normal sleep architecture, causes no morning grogginess, develops no tolerance requiring dose escalation, and demonstrates no withdrawal symptoms or addiction potential
Patients must be clearly informed of the risks associated with nonFDA-approved products, including potential contamination, inaccurate dosing, variable bioactivity, and the presence of impurities that may provoke adverse or unpredictable effects
It increases growth hormone receptor expression in tendon fibroblasts at both mRNA and protein levels, with effects lasting at least three days